枳壳及其主要活性成分对脾虚模型大鼠血清胃泌素、血浆乙酰胆碱、胃动素、P物质和血管活性肠肽的影响

发布时间：2018-01-31 12:37

本文关键词： 枳壳胃泌素乙酰胆碱胃动素 P物质血管活性肠肽　出处：《时珍国医国药》2017年05期 　论文类型：期刊论文

【摘要】：目的研究枳壳水煎液及其主要活性成分对脾虚模型大鼠血清胃泌素(GAS)、血浆乙酰胆碱(ACh)、胃动素(MTL)、P物质(SP)和血管活性肠肽(VIP)的影响。方法以苦寒泻下加饥饱失常法复制大鼠脾虚模型,枳壳水煎液及其主要活性成分分别灌胃给药后,采用ELISA法检测大鼠血清胃泌素、血浆乙酰胆碱、胃动素、P物质和血管活性肠肽的含量变化,观察各组给药后对脾虚模型大鼠胃肠激素的影响。结果与空白对照组比较,模型组大鼠中ACh、GAS、MTL和SP含量显著降低(P0.01),而VIP含量则显著升高(P0.05)。各组给药后,柚皮苷低、中、高剂量组血浆中ACh含量,柚皮苷低剂量组血浆中SP含量和柚皮苷低剂量组中VIP含量与模型组比较显著降低(P0.05,P0.01),而柚皮苷中、高剂量组血浆中SP含量和柚皮苷低、中剂量组血清中GAS含量则较模型组显著升高(P0.05,P0.01);新橙皮苷低剂量组血浆中ACh含量较模型组显著降低,而新橙皮苷高剂量组血浆中ACh含量,新橙皮苷低、中、高剂量组血浆中SP含量,新橙皮苷中、高剂量组血浆中MTL含量和新橙皮苷低、中、高剂量组血清中GAS含量则较模型组显著升高;两个单体组合物低剂量组血浆中ACh含量和两个单体组合物低、中剂量组血浆中VIP含量与模型组比较显著降低,而两个单体组合物中、高剂量组血浆中ACh含量,两个单体组合物高剂量组血浆中SP含量,两个单体组合物高剂量组血浆中MTL含量和两个单体组合物低、中、高剂量组血清中GAS含量则较模型组显著升高;枳壳水煎液低剂量组血浆中ACh含量与模型组比较显著降低,而枳壳水煎液高剂量组血浆中MTL含量和枳壳水煎液低、中、高剂量组血清中GAS含量则较模型组显著升高。结论枳壳可能通过升高血清中GAS、血浆中ACh、MTL、SP含量和抑制VIP的分泌来促进胃肠运动,这可能是枳壳治疗胃肠动力障碍性疾病的机制之一。
[Abstract]:Objective to study the effects of Fructus Aurantii decoction and its main active components on serum gastrin (gastrin), acetylcholine (ache) and motilin (MTL) in rats with spleen deficiency. Methods the spleen deficiency model of rats was induced by cold diarrhea plus hunger and satiety. The decoction of Fructus Aurantii Fructus Aurantii and its main active components were given orally. The changes of serum gastrin, plasma acetylcholine, motilin substance P and vasoactive intestinal peptide were detected by ELISA. To observe the effect of each group on gastrointestinal hormones in rats with spleen deficiency. Results compared with the blank control group, the MTL and SP contents of GASA in the model group were significantly lower than those in the control group (P 0.01). However, the content of VIP increased significantly (P 0.05). After administration of naringin, the content of ACh in plasma was low, medium and high dose groups. The SP content in plasma of naringin low dose group and VIP content in naringin low dose group were significantly lower than those in model group, while naringin was significantly decreased in naringin group. The content of SP and naringin in plasma of high dose group was lower than that of model group, while the content of GAS in serum of middle dose group was significantly higher than that of model group. Compared with the model group, the plasma ACh content in the low dose group was significantly lower than that in the model group, while the content of ACh in the plasma of the high dose group was lower than that in the model group, and the content of SP in the plasma was lower in the high dose group and the content of SP in the plasma was lower in the high dose group. The content of MTL and neopeperidin in plasma of high dose group was lower than that of model group, while the content of GAS in serum of high dose group was significantly higher than that of model group. The plasma ACh content and two monomer compositions were lower in the two monosomic compositions than in the model group, while the VIP content in the plasma in the middle dose group was significantly lower than that in the model group, while in the two monomer compositions, the content of VIP in the plasma was lower than that in the model group. ACh content in plasma of high dose group, SP content in plasma of high dose group of two monomer compositions, MTL content in plasma of high dose group of two monomer compositions and two monomer compositions were low and medium. The serum GAS content in the high dose group was significantly higher than that in the model group. Compared with the model group, the plasma ACh content in the low dose group of Fructus Aurantii decoction was significantly lower than that in the model group, while the content of MTL in the plasma and the decoction of Fructus Aurantii in the high dose group were lower and lower than those in the model group. The GAS content in serum of high dose group was significantly higher than that of model group. Conclusion it is possible that ACh-MTL in serum and plasma of Fructus aurantii aurantii can be increased. Sp content and inhibition of VIP secretion to promote gastrointestinal motility may be one of the mechanisms of Fructus Aurantii Fructus Aurantii in the treatment of gastrointestinal motility disorders.
【作者单位】：江西中医药大学现代中药制剂教育部重点实验室;
【基金】：国家自然科学基金(No.81460575;No.81260612)
【分类号】：R285.5;R-332
【正文快照】： 胃肠动力障碍是众多功能性胃肠病如胃食管反流、功能性消化不良及功能性便秘等共同的病理变化[1]。随着生活节奏的加快,精神压力的加重,胃肠动力障碍性疾病发病率剧增,严重影响了患者的生活质量。现代医学认为,人和动物内存在内分泌神经免疫网络,这一网络集三大信息传递于一体

【相似文献】